Document Detail

Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study.
MedLine Citation:
PMID:  16773617     Owner:  NLM     Status:  MEDLINE    
To investigate excessive daytime sleepiness (EDS) in patients with Parkinson's disease (PD), the reasons for which have not yet been clarified, polysomnography (PSG) and the Multiple Sleep Latency Test (MSLT) were performed in 46 patients with PD, and, in addition, PSG was performed in 30 healthy controls. Assessment included Epworth Sleepiness Score (ESS), Mini-Mental State Examination (MMSE), and Hamilton Test (HT) for depression. Fifty percent of PD patients reported EDS (ESS, 10 +/- 4.5 vs. 6.9 +/- 3.7; P = 0.01). Compared with controls, PD patients as a group had lower sleep efficiency (65 +/- 22 vs. 77 +/- 14; P = 0.03), a longer Stage 2 (73 +/- 12 vs. 67 +/- 12; P = 0.03), and a shorter rapid eye movement stage (8 +/- 8 vs. 17 +/- 8; P < 0.001). Clinical data and sleep characteristics were similar in PD with/without EDS. Of interest, patients treated with clonazepam (CLNZ) had lower EDS than those without CLNZ (ESS, 7.9 +/- 4.7 vs. 11.3 +/- 4.0; P = 0.03). These patients suffered less periodic leg movement during sleep (2.1 +/- 2.7 vs. 12.4 +/- 28; P = 0.04), which might explain the finding. No correlation was found between ESS, MSLT, and all other clinical features analyzed. In PD patients, according to the data obtained, severity of EDS does not depend on any specific clinical factor and the etiology is probably multifactorial. Paradoxically, PD patients treated with CLNZ were less sleepy than patients not treated with CLNZ.
Isaac Shpirer; Ala Miniovitz; Colin Klein; Richard Goldstein; Tatiana Prokhorov; Jack Theitler; Lea Pollak; Jose Martin Rabey
Related Documents :
11696027 - Non motor off in parkinson's disease.
11207397 - Role of the dopaminergic system in chronic pain -- a fluorodopa-pet study.
18450497 - Analysis of the lrrk2 gly2385arg variant in primary dystonia and multiple system atroph...
11459077 - Correlating rates of cerebral atrophy in parkinson's disease with measures of cognitive...
10796727 - Calcium channel blockers for acute traumatic brain injury.
6840897 - A method for the study of cryoglobulin solubilization curves at 37 degrees c. prelimina...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Movement disorders : official journal of the Movement Disorder Society     Volume:  21     ISSN:  0885-3185     ISO Abbreviation:  Mov. Disord.     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-09-27     Completed Date:  2007-02-02     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  8610688     Medline TA:  Mov Disord     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1432-8     Citation Subset:  IM    
Copyright Information:
(c) 2006 Movement Disorder Society.
Sleep Laboratory, Assaf Harofeh Medical Center, Zerifin, Israel, affiliated to Sackler School of Medicine, Tel Aviv University, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Antiparkinson Agents / therapeutic use
Benzodiazepines / therapeutic use
Clonazepam / therapeutic use
Cohort Studies
Disorders of Excessive Somnolence / diagnosis*,  drug therapy,  epidemiology
Dopamine Agonists / therapeutic use
Drug Therapy, Combination
Levodopa / therapeutic use
Middle Aged
Parkinson Disease / diagnosis*,  drug therapy,  epidemiology
Reference Values
Restless Legs Syndrome / diagnosis,  drug therapy,  epidemiology
Sleep Stages / drug effects
Wakefulness / drug effects
Reg. No./Substance:
0/Antiparkinson Agents; 0/Dopamine Agonists; 0/Levodopa; 12794-10-4/Benzodiazepines; 1622-61-3/Clonazepam
Comment In:
Mov Disord. 2007 Jul 30;22(10):1520-1   [PMID:  17486618 ]
Mov Disord. 2007 Jul 30;22(10):1520; author reply 1520-1   [PMID:  17534962 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome.
Next Document:  Special low-protein foods ameliorate postprandial off in patients with advanced Parkinson's disease.